title: Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
authors.forename: Alberto
authors.initials: A
authors.lastname: Calderón
authors.forename: Onofre
authors.initials: O
authors.lastname: Vegazo
authors.forename: Raúl
authors.initials: R
authors.lastname: Fernandez
authors.forename: Enrique
authors.initials: E
authors.lastname: Asín
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013777:Tetrazoles / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan